Last reviewed · How we verify
Neoantigen Vaccines
At a glance
| Generic name | Neoantigen Vaccines |
|---|---|
| Also known as | Personalized Neoantigen-based Dendritic Cell Vaccine |
| Sponsor | Chinese PLA General Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- General disorders and administration
- Respiratory, thoracic and mediastinal disorders
- Platelets-low
- Gastrointestinal disorders
- Glucose, serum-low (hypoglycemia)
- Rash/desquamation
- Leukocytes (total WBC) - low
- Pruritis/itching
- Hemoglobin-low
- Neutrophils/granulocytes (ANC/AGC) - low
- Infections and infestations
- Metabolism and nutrition disorders
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (PHASE1)
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (PHASE1)
- Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (PHASE1)
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG (PHASE1)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoantigen Vaccines CI brief — competitive landscape report
- Neoantigen Vaccines updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI